Ivan Pushkarsky
Principal investigator, leads FORCYTE BIOTECHNOLOGIES, INC..
MedtechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$4.1MFederal grants as PI11 awards
0Patents grantedNone matched
28Papers408 citations
Federal awards and patents by year
AwardsPatents
11 awards · $4.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 7, 2022 | NIH | SBIR Phase I Small molecule enhancers of detrusor contraction discovered using a functional cell contractility screen as therapeutic candidates for underactive bladder | $42K | FORCYTE BIOTECHNOLOGIES, INC. |
| Sep 14, 2021 | NIH | STTR Phase I Smart, integrated well-plates for ultra-high-throughput screening of excitation-contraction coupling in tissues | $350K | FORCYTE BIOTECHNOLOGIES, INC. with UNIVERSITY OF CALIFORNIA-IRVINE |
| Jun 14, 2021 | NIH | SBIR Phase I Small molecule enhancers of detrusor contraction discovered using a functional cell contractility screen as therapeutic candidates for underactive bladder | $353K | FORCYTE BIOTECHNOLOGIES, INC. |
| Jun 18, 2020 | NIH | SBIR Phase II Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension | $810K | FORCYTE BIOTECHNOLOGIES, INC. |
| May 14, 2020 | NIH | SBIR Phase II Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension | $66K | FORCYTE BIOTECHNOLOGIES, INC. |
| Aug 6, 2019 | NIH | SBIR Phase II Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension | $1.7M | FORCYTE BIOTECHNOLOGIES, INC. |
| Feb 6, 2019 | NIH | SBIR Phase I High-throughput screening of vasoprotectors in the brain using single-cell force mapping towards anti-migraine therapies | $22K | FORCYTE BIOTECHNOLOGIES, INC. |
| Sep 10, 2018 | NIH | SBIR Phase I High-throughput screening of vasoprotectors in the brain using single-cell force mapping towards anti-migraine therapies | $42K | FORCYTE BIOTECHNOLOGIES, INC. |
| Aug 1, 2018 | NIH | SBIR Phase I High-throughput screening of uterine smooth muscle contractility towards therapies to prevent pre-term birth | $225K | FORCYTE BIOTECHNOLOGIES, INC. |
| Apr 3, 2018 | NIH | SBIR Phase I High-throughput screening of vasoprotectors in the brain using single-cell force mapping towards anti-migraine therapies | $225K | FORCYTE BIOTECHNOLOGIES, INC. |
| 2018 | NIH | SBIR Phase I Multiplexed single-cell contractility assay to develop therapeutics for asthma and hypertension | $225K | FORCYTE BIOTECHNOLOGIES, INC. |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#411
Awards as PI#114
Patents#505
Companies
- FORCYTE BIOTECHNOLOGIES, INC.Leads (SEC Form D) · Medtech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.